Vericel Valuation Multiples

Vericel Overview

About Vericel

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Founded

1989

HQ

Employees

357

Website

vcel.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $290M

EBITDA: $76M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Vericel Financials

Vericel reported last 12-month revenue of $290M and EBITDA of $76M.

In the same LTM period, Vericel generated $217M in gross profit, $76M in EBITDA, and $18M in net income.

Vericel P&L

In the most recent fiscal year, Vericel reported revenue of $276M and EBITDA of $71M.

Vericel expects next 12-month revenue of XXX and NTM EBITDA of XXX

Vericel Stock Performance

Vericel has current market cap of $2B, and enterprise value of $2B.

Vericel's stock price is $35.69.

Vericel Valuation Multiples

Vericel trades at 6.1x EV/Revenue multiple, and 23.5x EV/EBITDA.

Vericel Financial Valuation Multiples

As of April 18, 2026, Vericel has market cap of $2B and EV of $2B.

Equity research analysts estimate Vericel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vericel has a P/E ratio of 98.4x.

Vericel Margins & Growth Rates

Vericel's revenue in the last 12 month grew by 17%.

Vericel's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.5M for the same period.

Vericel's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vericel's rule of X is 70% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Vericel Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Vericel M&A Activity

Vericel acquired XXX companies to date.

Last acquisition by Vericel was on XXXXXXXX, XXXXX. Vericel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Vericel Investment Activity

Vericel invested in XXX companies to date.

Vericel made its latest investment on XXXXXXXX, XXXXX. Vericel invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).